Israeli researchers find more than a fivefold risk of developing systemic sclerosis among people with vitiligo.
Research has shown that patients with vitiligo are disproportionately affected by a variety of other autoimmune diseases, including rheumatoid arthritis, alopecia areata and lupus erythematosus.
But less is known about the relationship between vitiligo and systemic sclerosis, a rare chronic condition that involves the buildup of scar tissue in the skin, joints and internal organs. Systemic sclerosis can result in pigment changes in the skin, including a loss of pigment that resembles vitiligo and a combination of loss and gain of pigment that causes a salt-and-pepper appearance.
A team of Israeli researchers led by Khalaf Kridin, M.D., Ph.D., used the database of Clalit Health Service, the largest HMO in Israel, to examine the relationship between vitiligo and systemic sclerosis. They identified close to 21,000 people in the database with vitiligo and a little over 100,000 who could serve as age-, sex- and ethnicity-matched control.
They reported their results in the Australian Journal of Dermatology earlier this month.
They found that the risk of developing systemic sclerosis was five times higher among the patients with vitiligo than the matched controls. The incidence rate of systemic sclerosis was 2.4 cases per 10,000 person-years among patients with vitiligo. Among the controls, it was 0.4 cases of 10,000 person-years.
In a smaller group of patients, Kridin and colleagues also looked at the risk of vitiligo among those a history of systemic sclerosis. After variety of statistical adjustments, they found that the risk of vitiligo was twice as high among people with systemic sclerosis.
Reasons for the association between vitiligo and systemic sclerosis were beyond the scope of this epidemiologic study, but Kridin and his colleagues shared some theories. Fibroblasts, the cells that product collagen and play a role in systemic sclerosis, affect pigmentation and therefore may play a causal role in vitiligo. Another possibility is that the autoimmune processes that cause vitiligo also play a role in causing systemic sclerosis.
Insights Into Chronic Itch From Shawn Kwatra, M.D.
April 15th 2025A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.
Read More
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Opzelura Topical Cream Drives Incyte's Record Growth in 2024 with 50% Revenue Surge
February 18th 2025Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.
Read More